Related Jobs
-
Clinical Research Assocaite
Job Type: Permanent
Salary: $ 30000.00 - $ 42000.00 per annum
Location: Russia - Moscow -
Study Authorisation Associate
Job Type: Permanent
Salary: € 20000.00 - € 25000.00 per annum
Location: Israel
Solvay discontinues research into potential obesity compound
17 Nov 2008
Clinical Research
Solvay has discontinued all research and development activities relating to a potential obesity treatment.
The company's investigational compound SLV319 was in phase-two development and, according to the company, recent results had "confirmed its clinical activity and its efficacy".
In the recent announcement of its financial results for the first nine months of the year, the firm had indicated that it was assessing its next step with regard to the compound.
"While the discontinuation is not related to any adverse events or the efficacy of the compound, we have made this decision after careful evaluation of the current regulatory environment ," commented Dr Claus Steinborn, head of global research and development.
A compound in its class now faces "new and high regulatory hurdles", he added.
Solvay recently revealed that its group net income for the first nine months of the year was down by 34 per cent compared to the same period in 2007.
It posted stable group sales of just over 7.2 billion euros (£6.1 billion).
